" class="no-js "lang="en-US"> NanoCellect - Medtech Alert
Monday, August 18, 2025
NanoCellect | Pharmtech Focus

NanoCellect

About NanoCellect

NanoCellect

NanoCellect is committed to empowering every scientist to make discoveries one cell at a time, with modern and simple technologies for to advance cell based assays that are affordable, compact, and easy-to-use. Our microfluidic flow cytometry platforms enable biomedical scientists to analyze and sort cells required for drug discovery, single cell-omics, cloning, and basic research. The company was founded in late 2009 as a spinout from UCSD and dedicated 6 years developing the foundation of the WOLF’s technology before introducing the WOLF to early adopters in 2016. Initial funding of R&D was graciously provided by multiple NIH SBIR grants and contracts. Additionally, we are backed by Illumina Ventures, FusionX Ventures, Anzu Partners, Agilent Technologies, Vertical Ventures and other private investors.

Related Story

Fluent BioSciences and NanoCellect Announce Joint Collaboration to Improve Resolution of Single-cell RNA Sequencing Analysis of Rare Cell Populations

June 20 2022

Fluent BioSciences, a biotechnology company focused on making single-cell analysis simple and accessible to every […]